{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:09:47Z","timestamp":1791925787828,"version":"4.3.4"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40348-018-0081-6","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T11:49:37Z","timestamp":1517917777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["The potential of antisense oligonucleotide therapies for inherited childhood lung diseases"],"prefix":"10.1186","volume":"5","author":[{"given":"Kelly M.","family":"Martinovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Kicic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve D.","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Stick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"81_CR1","doi-asserted-by":"crossref","unstructured":"Stein CA, Castanotto D (2017) FDA-approved oligonucleotide therapies in 2017. Mol Ther. 25(5): p. 1069\u20131075","DOI":"10.1016\/j.ymthe.2017.03.023"},{"key":"81_CR2","unstructured":"FDA grants accelerated approval to first drug for Duchenne muscular dystrophy. U.S. Food and Drug Administration news release 19th September 2016; Available from: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm521263.htm"},{"key":"81_CR3","unstructured":"FDA approves first drug for spinal muscular atrophy. U.S. Food and Drug Administration news release 23 December 2016; Available from: https:\/\/www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm534611.htm"},{"issue":"1","key":"81_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/gb4150","volume":"15","author":"T Sterne-Weiler","year":"2014","unstructured":"Sterne-Weiler T, Sanford JR (2014) Exon identity crisis: disease-causing mutations that disrupt the splicing code. Genome Biol 15(1):201\u2013201","journal-title":"Genome Biol"},{"issue":"5\u20136","key":"81_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1440-1681.2006.04403.x","volume":"33","author":"JH Chan","year":"2006","unstructured":"Chan JH, Lim S, Wong WS (2006) Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 33(5\u20136):533\u2013540","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"81_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova A, Watts JK (2017) The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotech 35(3):238\u2013248","journal-title":"Nat Biotech"},{"key":"81_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"MM Evers","year":"2015","unstructured":"Evers MM, Toonen LJ, van Roon-Mom WM (2015) Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 87:90\u2013103","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"81_CR8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1002\/ppul.23659","volume":"52","author":"ME McGarry","year":"2017","unstructured":"McGarry ME et al (2017) In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies. Pediatr Pulmonol 52(4):472\u2013479","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"81_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/pme.11.7","volume":"8","author":"EO Lillie","year":"2011","unstructured":"Lillie EO et al (2011) The n-of-1 clinical trial: the ultimate strategy for individualizing medicine? Per Med 8(2):161\u2013173","journal-title":"Per Med"},{"issue":"Supplement C","key":"81_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.csda.2016.09.006","volume":"113","author":"SF Williamson","year":"2017","unstructured":"Williamson SF et al (2017) A Bayesian adaptive design for clinical trials in rare diseases. Comput Statist Data Anal 113(Supplement C):136\u2013153","journal-title":"Comput Statist Data Anal"},{"issue":"Supplement C","key":"81_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.csda.2016.08.007","volume":"113","author":"H Schmidli","year":"2017","unstructured":"Schmidli H, Neuenschwander B, Friede T (2017) Meta-analytic-predictive use of historical variance data for the design and analysis of clinical trials. Comput Stat Data Anal 113(Supplement C):100\u2013110","journal-title":"Comput Stat Data Anal"},{"issue":"3","key":"81_CR12","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.ddstr.2012.12.001","volume":"10","author":"ST Crooke","year":"2013","unstructured":"Crooke ST (2013) RNA directed therapeutics: mechanisms and status. Drug Discov Today Therapeutic Strateg 10(3):e109\u2013e117","journal-title":"Drug Discov Today Therapeutic Strateg"},{"issue":"10","key":"81_CR13","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1038\/mt.2016.136","volume":"24","author":"ST Crooke","year":"2016","unstructured":"Crooke ST et al (2016) Integrated safety assessment of 2\u2032-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol Ther 24(10):1771\u20131782","journal-title":"Mol Ther"},{"issue":"8","key":"81_CR14","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1093\/nar\/gku142","volume":"42","author":"AD Burdick","year":"2014","unstructured":"Burdick AD et al (2014) Sequence motifs associated with hepatotoxicity of locked nucleic acid\u2014modified antisense oligonucleotides. Nucleic Acids Res 42(8):4882\u20134891","journal-title":"Nucleic Acids Res"},{"key":"81_CR15","doi-asserted-by":"crossref","unstructured":"Shen X, Corey DR (2017) Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. [Epub ahead of print]","DOI":"10.1093\/nar\/gkx1239"},{"issue":"1","key":"81_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1089\/nat.2013.0454","volume":"24","author":"P Jarver","year":"2014","unstructured":"Jarver P, O'Donovan L, Gait MJ (2014) A chemical view of oligonucleotides for exon skipping and related drug applications. Nucleic Acid Ther 24(1):37\u201347","journal-title":"Nucleic Acid Ther"},{"key":"81_CR17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 50:259\u2013293","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"81_CR18","first-page":"347","volume":"1","author":"N Dias","year":"2002","unstructured":"Dias N, Stein CA (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1(5):347\u2013355","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"81_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00003088-199528010-00002","volume":"28","author":"S Agrawal","year":"1995","unstructured":"Agrawal S et al (1995) Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet 28(1):7\u201316","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"81_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1089\/154545704322988067","volume":"14","author":"R Kole","year":"2004","unstructured":"Kole R, Vacek M, Williams T (2004) Modification of alternative splicing by antisense therapeutics. Oligonucleotides 14(1):65\u201374","journal-title":"Oligonucleotides"},{"issue":"14","key":"81_CR21","doi-asserted-by":"publisher","first-page":"6549","DOI":"10.1093\/nar\/gkw533","volume":"44","author":"MA Havens","year":"2016","unstructured":"Havens MA, Hastings ML (2016) Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res 44(14):6549\u20136563","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"81_CR22","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1073\/pnas.75.1.285","volume":"75","author":"ML Stephenson","year":"1978","unstructured":"Stephenson ML, Zamecnik PC (1978) Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 75(1):285\u2013288","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"81_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/nar\/7.1.179","volume":"7","author":"H Donis-Keller","year":"1979","unstructured":"Donis-Keller H (1979) Site specific enzymatic cleavage of RNA. Nucleic Acids Res 7(1):179\u2013192","journal-title":"Nucleic Acids Res"},{"key":"81_CR24","unstructured":"Roehr B (1998) Fomivirsen approved for CMV retinitis. J Int Assoc Physicians AIDS Care 4(10):14\u20136"},{"key":"81_CR25","volume-title":"Public statement on Vitravene (fomivirsen). The European Agency for the Evaluation of Medical Products","author":"N Wathion","year":"2002","unstructured":"Wathion, N. (2002) Public statement on Vitravene (fomivirsen). The European Agency for the Evaluation of Medical Products [cited 6th August 2002; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Public_statement\/2009\/12\/WC500018346.pdf . Cited on 19 July 2017"},{"issue":"2","key":"81_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"EWM Ng","year":"2006","unstructured":"Ng EWM et al (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5(2):123\u2013132","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"81_CR27","first-page":"119","volume":"39","author":"E Wong","year":"2014","unstructured":"Wong E, Goldberg T (2014) Mipomersen (Kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. Pharm Ther 39(2):119\u2013122","journal-title":"Pharm Ther"},{"issue":"18","key":"81_CR28","doi-asserted-by":"publisher","first-page":"8673","DOI":"10.1073\/pnas.90.18.8673","volume":"90","author":"Z Dominski","year":"1993","unstructured":"Dominski Z, Kole R (1993) Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci U S A 90(18):8673\u20138677","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"81_CR29","doi-asserted-by":"publisher","first-page":"9591","DOI":"10.1073\/pnas.97.17.9591","volume":"97","author":"G Lacerra","year":"2000","unstructured":"Lacerra G et al (2000) Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc Natl Acad Sci U S A 97(17):9591\u20139596","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"81_CR30","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0735-1097(02)01830-2","volume":"39","author":"NN Kipshidze","year":"2002","unstructured":"Kipshidze NN et al (2002) Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J Am Coll Cardiol 39(10):1686\u20131691","journal-title":"J Am Coll Cardiol"},{"key":"81_CR31","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3389\/fchem.2014.00087","volume":"2","author":"PM Moreno","year":"2014","unstructured":"Moreno PM, Pego AP (2014) Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. Front Chem 2:87","journal-title":"Front Chem"},{"issue":"6","key":"81_CR32","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CCO.0000000000000127","volume":"26","author":"D Castanotto","year":"2014","unstructured":"Castanotto D, Stein CA (2014) Antisense oligonucleotides in cancer. Curr Opin Oncol 26(6):584\u2013589","journal-title":"Curr Opin Oncol"},{"issue":"3","key":"81_CR33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s12035-014-8724-7","volume":"50","author":"G Riboldi","year":"2014","unstructured":"Riboldi G et al (2014) Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS\/FTD diseases. Mol Neurobiol 50(3):721\u2013732","journal-title":"Mol Neurobiol"},{"issue":"11","key":"81_CR34","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/mds.26020","volume":"29","author":"N Aronin","year":"2014","unstructured":"Aronin N, DiFiglia M (2014) Huntingtin-lowering strategies in Huntington\u2019s disease: antisense oligonucleotides, small RNAs, and gene editing. Mov Disord 29(11):1455\u20131461","journal-title":"Mov Disord"},{"key":"81_CR35","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1038\/mtna.2014.8","volume":"3","author":"KL Greer","year":"2014","unstructured":"Greer KL et al (2014) Targeted exon skipping to correct exon duplications in the dystrophin gene. Mol Ther Nucleic Acids 3:e155","journal-title":"Mol Ther Nucleic Acids"},{"key":"81_CR36","doi-asserted-by":"crossref","unstructured":"Kinane TB, et al (2017) Long-term pulmonary function in Duchenne muscular dystrophy: comparison of eteplirsen-treated patients to natural history. J Neuromuscul Dis. [Epub ahead of print]","DOI":"10.3233\/JND-170272"},{"key":"81_CR37","unstructured":"Sarepta Therapeutics, I., (2017) Sarepta Therapeutics announces positive results in its study evaluating gene expression, dystrophin production, and dystrophin localization in patients with Duchenne muscular dystrophy (DMD) amenable to skipping exon 53 treated with golodirsen (SRP-4053), I. Estepan, Editor.: http:\/\/investorrelations.sarepta.com"},{"issue":"6","key":"81_CR38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1517\/14712598.7.6.831","volume":"7","author":"T Yokota","year":"2007","unstructured":"Yokota T et al (2007) Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther 7(6):831\u2013842","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"81_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.nmd.2011.10.007","volume":"22","author":"CF Adkin","year":"2012","unstructured":"Adkin CF et al (2012) Multiple exon skipping strategies to by-pass dystrophin mutations. Neuromuscul Disord 22(4):297\u2013305","journal-title":"Neuromuscul Disord"},{"key":"81_CR40","first-page":"53776","volume":"111","author":"B Miskew Nichols","year":"2016","unstructured":"Miskew Nichols B et al (2016) Multi-exon skipping using cocktail antisense oligonucleotides in the canine X-linked muscular dystrophy. J Vis Exp 111:53776","journal-title":"J Vis Exp"},{"issue":"7","key":"81_CR41","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/sj.mt.6300095","volume":"15","author":"SD Wilton","year":"2007","unstructured":"Wilton SD et al (2007) Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 15(7):1288\u20131296","journal-title":"Mol Ther"},{"issue":"2","key":"81_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/humu.20428","volume":"28","author":"C B\u00e9roud","year":"2007","unstructured":"B\u00e9roud C et al (2007) Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 28(2):196\u2013202","journal-title":"Hum Mutat"},{"issue":"1","key":"81_CR43","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80(1):155\u2013165","journal-title":"Cell"},{"issue":"11","key":"81_CR44","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL et al (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci 96(11):6307\u20136311","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"81_CR45","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","volume":"26","author":"NK Singh","year":"2006","unstructured":"Singh NK et al (2006) Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol Cell Biol 26(4):1333\u20131346","journal-title":"Mol Cell Biol"},{"issue":"10063","key":"81_CR46","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS et al (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388(10063):3017\u20133026","journal-title":"Lancet"},{"issue":"6","key":"81_CR47","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1358\/dot.2017.53.6.2652413","volume":"53","author":"DM Paton","year":"2017","unstructured":"Paton DM (2017) Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy. Drugs Today (Barc) 53(6):327\u2013337","journal-title":"Drugs Today (Barc)"},{"issue":"12","key":"81_CR48","doi-asserted-by":"publisher","first-page":"a009480","DOI":"10.1101\/cshperspect.a009480","volume":"2","author":"C Ferec","year":"2012","unstructured":"Ferec C, Cutting GR (2012) Assessing the disease-liability of mutations in CFTR. Cold Spring Harb Perspect Med 2(12):a009480","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"2","key":"81_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.pharmthera.2009.10.006","volume":"125","author":"JL Kreindler","year":"2010","unstructured":"Kreindler JL (2010) Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies. Pharmacol Ther 125(2):219\u2013229","journal-title":"Pharmacol Ther"},{"key":"81_CR50","unstructured":"Rommens DJM (2011) CFTR Mutation Database. Hospital for Sick Children"},{"issue":"7","key":"81_CR51","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-R","volume":"73","author":"MJ Welsh","year":"1993","unstructured":"Welsh MJ, Smith AE (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73(7):1251\u20131254","journal-title":"Cell"},{"issue":"21","key":"81_CR52","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","volume":"363","author":"FJ Accurso","year":"2010","unstructured":"Accurso FJ et al (2010) Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363(21):1991\u20132003","journal-title":"N Engl J Med"},{"issue":"44","key":"81_CR53","doi-asserted-by":"publisher","first-page":"18825","DOI":"10.1073\/pnas.0904709106","volume":"106","author":"F Van Goor","year":"2009","unstructured":"Van Goor F et al (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci 106(44):18825\u201318830","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"81_CR54","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright CE et al (2015) Lumacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR. N Engl J Med 373(3):220\u2013231","journal-title":"N Engl J Med"},{"key":"81_CR55","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S1569-1993(15)30002-3","volume":"14","author":"W Beumer","year":"2015","unstructured":"Beumer W et al (2015) WS01.2 QR-010, an RNA therapy, restores CFTR function using in vitro and in vivo models of \u0394F508 CFTR. J Cyst Fibros 14:S1","journal-title":"J Cyst Fibros"},{"issue":"21","key":"81_CR56","doi-asserted-by":"publisher","first-page":"8150","DOI":"10.1073\/pnas.0401933101","volume":"101","author":"PC Zamecnik","year":"2004","unstructured":"Zamecnik PC et al (2004) Reversal of cystic fibrosis phenotype in a cultured Delta508 cystic fibrosis transmembrane conductance regulator cell line by oligonucleotide insertion. Proc Natl Acad Sci U S A 101(21):8150\u20138155","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"81_CR57","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1183\/09031936.01.00057001","volume":"17","author":"RJ Massie","year":"2001","unstructured":"Massie RJ et al (2001) Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J 17(6):1195\u20131200","journal-title":"Eur Respir J"},{"issue":"4","key":"81_CR58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2164\/jandrol.106.002337","volume":"28","author":"R Radpour","year":"2007","unstructured":"Radpour R et al (2007) Molecular study of (TG)m(T)n polymorphisms in Iranian males with congenital bilateral absence of the vas deferens. J Androl 28(4):541\u2013547","journal-title":"J Androl"},{"issue":"6","key":"81_CR59","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/j.1460-2075.1991.tb07655.x","volume":"10","author":"CS Chu","year":"1991","unstructured":"Chu CS et al (1991) Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. EMBO J 10(6):1355\u20131363","journal-title":"EMBO J"},{"issue":"2","key":"81_CR60","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/humu.22931","volume":"37","author":"S Igreja","year":"2016","unstructured":"Igreja S et al (2016) Correction of a cystic fibrosis splicing mutation by antisense oligonucleotides. Hum Mutat 37(2):209\u2013215","journal-title":"Hum Mutat"},{"issue":"3","key":"81_CR61","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1002\/ajmg.a.30823","volume":"136","author":"A Quint","year":"2005","unstructured":"Quint A et al (2005) Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. Am J Med Genet A 136(3):246\u2013248","journal-title":"Am J Med Genet A"},{"issue":"51","key":"81_CR62","doi-asserted-by":"publisher","first-page":"36193","DOI":"10.1074\/jbc.274.51.36193","volume":"274","author":"KJ Friedman","year":"1999","unstructured":"Friedman KJ et al (1999) Correction of aberrant splicing of the cystic fibrosis transmembrane conductance regulator (CFTR) gene by antisense oligonucleotides. J Biol Chem 274(51):36193\u201336199","journal-title":"J Biol Chem"},{"issue":"15","key":"81_CR63","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1056\/NEJM199410133311503","volume":"331","author":"WE Highsmith","year":"1994","unstructured":"Highsmith WE et al (1994) A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 331(15):974\u2013980","journal-title":"N Engl J Med"},{"issue":"6","key":"81_CR64","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1183\/09031936.99.13614779","volume":"13","author":"M Griese","year":"1999","unstructured":"Griese M (1999) Pulmonary surfactant in health and human lung diseases: state of the art. Eur Respir J 13(6):1455\u20131476","journal-title":"Eur Respir J"},{"issue":"4","key":"81_CR65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2350\/09-01-0586.1","volume":"12","author":"SE Wert","year":"2009","unstructured":"Wert SE, Whitsett JA, Nogee LM (2009) Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol 12(4):253\u2013274","journal-title":"Pediatr Dev Pathol"},{"key":"81_CR66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1146\/annurev-pathol-012513-104644","volume":"10","author":"JA Whitsett","year":"2015","unstructured":"Whitsett JA, Wert SE, Weaver TE (2015) Diseases of pulmonary surfactant homeostasis. Annu Rev Pathol 10:371\u2013393","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"81_CR67","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/archdischild-2012-303143","volume":"102","author":"A Gupta","year":"2017","unstructured":"Gupta A, Zheng SL (2017) Genetic disorders of surfactant protein dysfunction: when to consider and how to investigate. Arch Dis Child 102(1):84\u201390","journal-title":"Arch Dis Child"},{"issue":"4","key":"81_CR68","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.prrv.2011.01.005","volume":"12","author":"WA Gower","year":"2011","unstructured":"Gower WA, Nogee LM (2011) Surfactant dysfunction. Paediatr Respir Rev 12(4):223\u2013229","journal-title":"Paediatr Respir Rev"},{"issue":"10","key":"81_CR69","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1542\/neo.9-10-e468","volume":"9","author":"A Faro","year":"2008","unstructured":"Faro A, Hamvas A (2008) Lung transplantation for inherited disorders of surfactant metabolism. NeoReviews 9(10):e468\u2013e476","journal-title":"NeoReviews"},{"issue":"20","key":"81_CR70","first-page":"2943","volume":"123","author":"A Hamvas","year":"2010","unstructured":"Hamvas A (2010) Evaluation and management of inherited disorders of surfactant metabolism. Chin Med J 123(20):2943\u20132947","journal-title":"Chin Med J"},{"issue":"3","key":"81_CR71","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/ppul.22811","volume":"49","author":"M Williamson","year":"2014","unstructured":"Williamson M, Wallis C (2014) Ten-year follow up of hydroxychloroquine treatment for ABCA3 deficiency. Pediatr Pulmonol 49(3):299\u2013301","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"81_CR72","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1164\/ajrccm.186.8.807","volume":"186","author":"J Don Hayes","year":"2012","unstructured":"Don Hayes J et al (2012) ABCA3 transporter deficiency. Am J Respir Crit Care Med 186(8):807\u2013807","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"81_CR73","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1164\/rccm.201107-1174CI","volume":"185","author":"FM de Benedictis","year":"2012","unstructured":"de Benedictis FM, Bush A (2012) Corticosteroids in respiratory diseases in children. Am J Respir Crit Care Med 185(1):12\u201323","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"81_CR74","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1164\/rccm.201402-0342OC","volume":"189","author":"JA Wambach","year":"2014","unstructured":"Wambach JA et al (2014) Genotype-phenotype correlations for infants and children with ABCA3 deficiency. Am J Respir Crit Care Med 189(12):1538\u20131543","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"81_CR75","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/pr.2012.21","volume":"71","author":"A Agrawal","year":"2012","unstructured":"Agrawal A et al (2012) An intronic ABCA3 mutation that is responsible for respiratory disease. Pediatr Res 71(6):633\u2013637","journal-title":"Pediatr Res"},{"issue":"6","key":"81_CR76","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1165\/ajrcmb.26.6.f241","volume":"26","author":"LM Nogee","year":"2002","unstructured":"Nogee LM (2002) Abnormal expression of surfactant protein C and lung disease. Am J Respir Cell Mol Biol 26(6):641\u2013644","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"22","key":"81_CR77","doi-asserted-by":"publisher","first-page":"19929","DOI":"10.1074\/jbc.M201537200","volume":"277","author":"W-J Wang","year":"2002","unstructured":"Wang W-J et al (2002) Biosynthesis of surfactant protein C (SP-C): sorting of SP-C proprotein involves homomeric association via a signal anchor domain. J Biol Chem 277(22):19929\u201319937","journal-title":"J Biol Chem"},{"issue":"6","key":"81_CR78","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1165\/rcmb.2005-0009OC","volume":"32","author":"S Mulugeta","year":"2005","unstructured":"Mulugeta S et al (2005) A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol 32(6):521\u2013530","journal-title":"Am J Respir Cell Mol Biol"},{"key":"81_CR79","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS et al (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351","journal-title":"Adv Drug Deliv Rev"},{"issue":"12","key":"81_CR80","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1038\/mt.2011.206","volume":"19","author":"SA Moschos","year":"2011","unstructured":"Moschos SA et al (2011) Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther 19(12):2163\u20132168","journal-title":"Mol Ther"},{"issue":"34","key":"81_CR81","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.2174\/138161208786898851","volume":"14","author":"SA Moschos","year":"2008","unstructured":"Moschos SA et al (2008) Targeting the lung using siRNA and antisense based oligonucleotides. Curr Pharm Des 14(34):3620\u20133627","journal-title":"Curr Pharm Des"},{"key":"81_CR82","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2016.10.009","volume":"169","author":"SA Moschos","year":"2017","unstructured":"Moschos SA, Usher L, Lindsay MA (2017) Clinical potential of oligonucleotide-based therapeutics in the respiratory system. Pharmacol Ther 169:83\u2013103","journal-title":"Pharmacol Ther"},{"issue":"8","key":"81_CR83","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3109\/08958378.2014.907587","volume":"26","author":"RA Fey","year":"2014","unstructured":"Fey RA et al (2014) Local and systemic tolerability of a 2\u2032O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-alpha delivery by inhalation in mouse and monkey. Inhal Toxicol 26(8):452\u2013463","journal-title":"Inhal Toxicol"},{"issue":"3","key":"81_CR84","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1165\/rcmb.2005-0456OC","volume":"36","author":"JG Karras","year":"2007","unstructured":"Karras JG et al (2007) Anti-inflammatory activity of inhaled IL-4 receptor-alpha antisense oligonucleotide in mice. Am J Respir Cell Mol Biol 36(3):276\u2013285","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"81_CR85","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1165\/ajrcmb.24.2.4237","volume":"24","author":"E Lach-Trifilieff","year":"2001","unstructured":"Lach-Trifilieff E et al (2001) In vitro and in vivo inhibition of interleukin (IL)-5-mediated eosinopoiesis by murine IL-5Ralpha antisense oligonucleotide. Am J Respir Cell Mol Biol 24(2):116\u2013122","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"6","key":"81_CR86","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1164\/rccm.200408-1006OC","volume":"171","author":"W Duan","year":"2005","unstructured":"Duan W et al (2005) Inhaled p38alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit Care Med 171(6):571\u2013578","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"81_CR87","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1124\/jpet.106.119214","volume":"321","author":"JR Crosby","year":"2007","unstructured":"Crosby JR et al (2007) Inhaled CD86 antisense oligonucleotide suppresses pulmonary inflammation and airway hyper-responsiveness in allergic mice. J Pharmacol Exp Ther 321(3):938\u2013946","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"81_CR88","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/nrg3763","volume":"15","author":"H Yin","year":"2014","unstructured":"Yin H et al (2014) Non-viral vectors for gene-based therapy. Nat Rev Genet 15(8):541\u2013555","journal-title":"Nat Rev Genet"},{"issue":"2","key":"81_CR89","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1006\/bbrc.1999.1548","volume":"264","author":"L Mologni","year":"1999","unstructured":"Mologni L, Nielsen PE, Gambacorti-Passerini C (1999) In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid. Biochem Biophys Res Commun 264(2):537\u2013543","journal-title":"Biochem Biophys Res Commun"},{"issue":"14","key":"81_CR90","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.2217\/nnm.15.61","volume":"10","author":"J Zhao","year":"2015","unstructured":"Zhao J, Feng SS (2015) Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. Nanomedicine (Lond) 10(14):2199\u20132228","journal-title":"Nanomedicine (Lond)"},{"issue":"4","key":"81_CR91","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1021\/mp400703d","volume":"11","author":"Q Yang","year":"2014","unstructured":"Yang Q et al (2014) Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol Pharm 11(4):1250\u20131258","journal-title":"Mol Pharm"},{"issue":"14","key":"81_CR92","doi-asserted-by":"publisher","first-page":"6518","DOI":"10.1093\/nar\/gkw236","volume":"44","author":"RL Juliano","year":"2016","unstructured":"Juliano RL (2016) The delivery of therapeutic oligonucleotides. Nucleic Acids Res 44(14):6518\u20136548","journal-title":"Nucleic Acids Res"},{"key":"81_CR93","doi-asserted-by":"crossref","unstructured":"Ugarte-Uribe B, et al (2016) Lipid-modified oligonucleotide conjugates: insights into gene silencing, interaction with model membranes and cellular uptake mechanisms. Bioorg Med Chem 25(1):175\u2013186","DOI":"10.1016\/j.bmc.2016.10.024"},{"issue":"8","key":"81_CR94","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1093\/nar\/gkn115","volume":"36","author":"MR Alam","year":"2008","unstructured":"Alam MR et al (2008) Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res 36(8):2764\u20132776","journal-title":"Nucleic Acids Res"},{"issue":"12","key":"81_CR95","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.4155\/tde.13.118","volume":"4","author":"JP Dassie","year":"2013","unstructured":"Dassie JP, Giangrande PH (2013) Current progress on aptamer-targeted oligonucleotide therapeutics. Ther Deliv 4(12):1527\u20131546","journal-title":"Ther Deliv"},{"issue":"8","key":"81_CR96","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/nm897","volume":"9","author":"QL Lu","year":"2003","unstructured":"Lu QL et al (2003) Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9(8):1009\u20131014","journal-title":"Nat Med"},{"key":"81_CR97","doi-asserted-by":"publisher","first-page":"10981","DOI":"10.1038\/ncomms10981","volume":"7","author":"G Han","year":"2016","unstructured":"Han G et al (2016) Hexose enhances oligonucleotide delivery and exon skipping in dystrophin-deficient mdx mice. Nat Commun 7:10981","journal-title":"Nat Commun"},{"issue":"3","key":"81_CR98","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nbt.3779","volume":"35","author":"ST Crooke","year":"2017","unstructured":"Crooke ST et al (2017) Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol 35(3):230\u2013237","journal-title":"Nat Biotechnol"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40348-018-0081-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-018-0081-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-018-0081-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T23:43:24Z","timestamp":1660434204000},"score":1,"resource":{"primary":{"URL":"https:\/\/molcellped.springeropen.com\/articles\/10.1186\/s40348-018-0081-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["81"],"URL":"https:\/\/doi.org\/10.1186\/s40348-018-0081-6","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"15 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"3"}}